Royalty Increases Bid as Elan Unveils Acquisitions


May 22, 2013

PharmaTimes Online

Just as Elan Corp. announced a range of transactions "designed to decisively transform and advance the company", Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker.

A week after announcing a $1 billion deal giving it access to royalties from Theravance's four respiratory drugs partnered with GlaxoSmithKline, Elan is paying 263.5 million euros in cash and shares (and possibly another 270 million euros) to acquire Austria's AOP Orphan Pharmaceuticals and will buy a 48% stake in Dubai's NewBridge Pharmaceuticals for $40 million. Read the full story
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments